MOESM2 of Non-coding RNAs underlie genetic predisposition to breast cancer

Additional file 2: Table S1. Breast derived samples on which RNA CaptureSeq was performed. Table S2. Expression (FPKM) of the mencRNAs across all RNA CaptureSeq samples. Table S3. Breast cancer risk signals and surrounding regions captured by RNA CaptureSeq. Table S4. Control sequences captured by RNA CaptureSeq. Table S5. MencRNAs with FPKM ≥0.5 identified by RNA CaptureSeq. Table S6. Novel mencRNAs with FPKM ≥0.5. Those overlapping with GENCODE, FANTOM-CAT, or NONCODE lncRNAs have been excluded. Table S7. Coding potential of the transcripts from mencRNAs with FPKM ≥0.5 assessed by coding potential calculator (CPC2). Table S8. MencRNAs differentially expressed between MCF7 estrogen-treated and control samples (FDR

附加文件2：表S1。接受RNA捕获测序（RNA CaptureSeq）的乳腺来源样本。表S2。所有RNA捕获测序样本中mencRNAs的表达量（每百万比对读段对应的每千碱基转录本片段数，FPKM）。表S3。RNA捕获测序捕获的乳腺癌风险信号及其侧翼区域。表S4。RNA捕获测序捕获的对照序列。表S5。经RNA捕获测序鉴定的FPKM≥0.5的mencRNAs。表S6。FPKM≥0.5的新型mencRNAs，已排除与GENCODE、FANTOM-CAT或NONCODE长链非编码RNA（long non-coding RNAs，lncRNAs）存在序列重叠的转录本。表S7。采用编码潜能计算器（CPC2）对FPKM≥0.5的mencRNAs的转录本进行编码潜能评估的结果。表S8。经雌激素处理的MCF7细胞与对照样本间差异表达的mencRNAs（错误发现率，False Discovery Rate，FDR）